Affy Marks End of 'Days of Fixed Content Arrays,' Reaffirms Sequencing Not a 'Strategic Fit' | GenomeWeb

By Justin Petrone

Still not interested in getting into the next-generation sequencing market, Affymetrix will instead continue to focus on making more flexible genotyping and gene-expression array formats and on new Panomics kits, according to the firm's CEO.

Kevin King said that while Affy may revisit the idea of becoming a player in the next-gen sequencing market "perhaps in the future," its current focus is on "leading in exploration and growing our business in validation and routine testing."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.